Developing a new medicine is often seen as the biggest driver of innovation in the pharmaceutical industry. But sometimes, the greater challenge is producing enough of an existing medicine to meet growing demand.

That is the problem Australian biotechnology company CSL is trying to address.

The company has announced that it will begin clinical trials for a new manufacturing process designed to produce more immunoglobulin from the same amount of donated human plasma. The trials, expected to begin in mid-2027, will support regulatory approval for the company’s proprietary Horizon 2 technology following discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Unlike a conventional clinical trial for a new drug, this study is intended to validate a new way of manufacturing an existing therapy.

Improving Production Rather Than Inventing a New Medicine

The announcement is not about discovering a new treatment.

Immunoglobulin is already an established therapy used worldwide to treat patients with immune deficiencies, certain neurological disorders, and a range of autoimmune diseases. These medicines are made from antibodies collected from donated human plasma and are often life-saving for patients whose immune systems cannot produce enough protective antibodies on their own.

The challenge is that plasma is a limited biological resource. Every dose of immunoglobulin begins with donated plasma, meaning production ultimately depends on the willingness of people to donate and the industry’s ability to process that plasma efficiently.

CSL’s Horizon 2 technology is designed to address the second part of that equation. Rather than increasing the volume of plasma collected, the new manufacturing process aims to extract more immunoglobulin from the same amount of donated plasma, improving the productivity of an already scarce resource.

Why Clinical Trials Are Necessary

Although the medicine itself is not changing, a significant change in how it is manufactured still requires regulatory scrutiny.

Manufacturing processes can influence the characteristics of biological medicines, and regulators must ensure that products made using a new process remain as safe, effective, and consistent as those produced using the existing one.

For that reason, CSL will conduct clinical studies using material manufactured at its Broadmeadows facility in Melbourne before seeking regulatory approval from the FDA and EMA.

Only after regulators are satisfied that the new process produces an equivalent product can Horizon 2 be adopted for commercial production.

Why Manufacturing Innovation Matters

Pharmaceutical innovation is often associated with discovering entirely new medicines. Equally important, however, are innovations that improve how medicines are produced.

Unlike chemically synthesized drugs, immunoglobulin cannot be manufactured from basic industrial ingredients. It is derived from antibodies found in donated human plasma, making the availability of raw material one of the industry’s biggest constraints.

Any technology that increases the amount of medicine obtained from each plasma donation has the potential to expand supply without requiring a corresponding increase in plasma collection.

For manufacturers, that can improve production efficiency and reduce pressure on an already resource-intensive supply chain. For healthcare systems and patients, it could help ease shortages of therapies that are increasingly in demand around the world.

Why This Matters for CSL

CSL is one of the world’s largest producers of plasma-derived therapies through its CSL Behring business.

As demand for immunoglobulin continues to rise, improving manufacturing efficiency has become strategically important. Expanding plasma collection networks requires significant investment, regulatory approvals, and time. Increasing output from existing plasma supplies offers another path to meeting future demand.

If Horizon 2 receives regulatory approval, CSL could strengthen its manufacturing capacity without relying solely on collecting more plasma, potentially improving both operational efficiency and long-term competitiveness.

A Broader Shift in Biopharmaceutical Manufacturing

The announcement also reflects a broader trend across advanced manufacturing industries.

As biological therapies become more widely used, companies are looking beyond new drug discovery and investing in process innovation to make existing treatments more efficient to produce. Improvements in manufacturing technology can increase capacity, reduce waste, and make better use of limited biological resources without changing the underlying medicine.

In that sense, the value of Horizon 2 lies not in creating a new therapy, but in improving how one of the world’s most important plasma-derived medicines is made.

The clinical trials announced by CSL are still an early step, and regulatory approval remains necessary before the technology can be used commercially. Even so, the development highlights an increasingly important reality in modern biotechnology: future gains may come not only from discovering new medicines, but also from finding better ways to manufacture the ones patients already depend on.